Search published articles

Showing 6 results for Shahrokh Tehraninejad

Ensieh Shahrokh Tehraninejad, Fatemeh Ramezanzadeh, Roya Nasiri, Mina Jafarabadi, Mohammad Sarafraz Yazdi,
Volume 8, Issue 3 (7-2010)

Background: Ovulation induction and ART may be a newly recognized cause of vascular thrombosis in unusual sites in otherwise healthy women. Objective: To report a case of thrombosis in right carotid artery 2.5 months after ovarian stimulation for IVF-ET.
Case report: A non pregnant 39-year-old woman without coagulation disorder and ovarian hyperstimulation syndrome (OHSS). The patient underwent two consecutive cycles of IVF-ET with administration of recombinant FSH and chorionic gonadotropin (10000 IU) in each cycle. The patient case had thrombosis of the carotid artery with clinical signs 2.5 months later while fasting in Ramadan. Thorough laboratory and imaging investigation revealed no causative factor.
Conclusion: Fasting may trigger thromboembolic complication weeks after ovarian stimulation.
Batool Rashidi, Roya Nasiri, Haleh Rahmanpour, Ensieh Shahrokh Tehraninejad , Maryam Deldar,
Volume 9, Issue 4 (7-2011)

Background: The differential efficacy between long GnRH agonist with antagonist can partly be due to the preexisting differences in the early antral follicles before ovarian stimulation.
Objective: To compare the effect of pretreatment by estradiol with GnRH antagonist on antral follicular size coordination and basal hormone levels in GNRH antagonist protocol.
Materials and Methods: On cycle day 3 (control/day 3), women underwent measurements of early antral follicles by ultrasound and serum FSH and ovarian hormones then were randomized to receive oral estradiol 4mg/day (n=15) or 3mg cetrorelix acetate (n=15) in luteal phase before subsequent antagonist protocol. Participants were re-evaluated as on control/day 3.
Results: There was a significant reduction of mean follicular sizes in each group after medical intervention (7.63±2.11 Vs. 4.30±0.92 in group A and 8.73±1.96 Vs. 4.13±1.11 in group B) (p=0.0001). The magnitude of follicular size reduction was significantly higher in group B (-4.60±2.04 Vs. -3.33±2.28) (0.027). There was a non significant attenuation of follicular size discrepancies in two groups. FSH and inhibin B levels in the day 3 of the next cycle in both groups were significantly decreased but did not have significant difference between two groups.
Conclusion: Both luteal E2 and premenstrual GnRH antagonist administration reduces the follicular sizes significantly and GnRH antagonist acts more potently than E2 in this way but attenuation of follicular size discrepancies in both treatment is not significant
Fatemeh Davari-Tanha, Ensieh Shahrokh Tehraninejad, Mohadese Ghazi, Zahra Shahraki,
Volume 14, Issue 12 (12-2016)

Background: Recurrent implantation failure (RIF) is the absence of implantationafter three consecutive In Vitro Fertilization (IVF) cycles with transferring at leastfour good quality embryos in a minimum of three fresh or frozen cycles in a womanunder 40 years. The definition and management of RIF is under constant scrutiny.
Objective: To investigate the effects of Granulocyte colony stimulating factor (GCSF)on RIF, pregnancy rate, abortion rate and implantation rates.
Materials and Methods: A double blind placebo controlled randomized trial wasconducted at two tertiary university based hospitals. One hundred patients with thehistory of RIF from December 2011 until January 2014 were recruited in the study.G-CSF 300μg/1ml was administered at the day of oocyte puncture or day ofprogesterone administration of FET cycle. Forty patients were recruited at G-CSFgroup, 40 in saline and 20 in placebo group.
Results: The mean age for whole study group was 35.3±4.2 yrs (G-CSF 35.5±4.32,saline 35.3±3.98, placebo 35.4±4.01, respectively). Seventeen patients had a positivepregnancy test after embryo transfer [10 (25%) in G-CSF; 5 (12.5%) in saline; and 2(10%) in placebo group]. The mean of abortion rates was 17.6% (3), two of them inG-CSF, one in saline group. The implantation rate was 12.3% in G-CSF, 6.1% insaline and 4.7% in placebo group.
Conclusion: G-CSF may increase chemical pregnancy and implantation rate inpatients with recurrent implantation failure but clinical pregnancy rate and abortionrate was unaffected.
Ensieh Shahrokh Tehraninejad, Mina Farshbaf Taghinejad, Batool Hossein Rashidi, Fedyeh Haghollahi,
Volume 15, Issue 7 (8-2017)

Background: Different combination of gonadotropin preparation has been introduced with no definite superiority of one over others in in vitro fertilization (IVF), but individualized regimens for each patient are needed.
Objective: The aim of the present study was to investigate the effect of controlled ovarian stimulation with recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH) versus human menopausal gonadotropin (HMG) plus r-FSH on fertility outcomes in IVF patients.
Materials and Methods: This is a randomized clinical trial study that was performed from October 2014-April 2016 on 140 infertile patients with a set of inclusion criteria that referred to infertility clinics in Vali- asr and Gandhi Hospital in Tehran. The women were randomly divided into two treatment groups. The first group (n=70) received rFSH from the second day of cycle and was added HMG in 6th day and the 2nd group (n=70), received rFSH from the second day of cycle and was added recombinant-LH in 6th day. Then ovum Pick-Up and embryo transfer were performed. In this study, we assessed the outcomes such as; chemical and clinical pregnancy rate, live birth and abortion rate.
Results: Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p>0.05). Total number of fetuses were significantly higher in patients who received rFSH + HMG (p=0.02). Fertility outcomes consisted of: live birth rate, chemical pregnancy and clinical pregnancy rate were higher in rFSH + HMG group in comparison to rFSH +r-LH group (p<0.05).
Conclusion: It seems that in IVF patients, HMG + rFSH used for controlled ovarian hyperstimulation have better effects on fertility outcomes, but in order to verify the results, it is recommended to implement studies on more patients.
Ensieh Shahrokh Tehraninejad, Roya Kabodmehri, Batol Hosein Rashidi, Mina Jafarabadi, Fateme Keikha, Masomeh Masomi, Fedieh Hagholahi,
Volume 16, Issue 1 (January 2018)

Background: Estrogen and progesterone are two crucial factors for endometrial preparation in frozen embryo transfer (FET) cycles. Studies assessing different forms of estradiol in FET have published already but literature lacks enough surveys on transdermal estrogen application in reproductive medicine.
Objective: To investigate the effects of trans dermal estrogen (Oestrogel) on pregnancy rates in patients that candidate for FET cycle.
Materials and Methods: In this randomized clinical trial, 100 women undergoing FET cycles referred to Imam Khomeeini Hospital were enrolled in two groups, randomly. Group I received 8 mg/day estradiol valerate (E2 tablet) orally and group II were treated with 6 mg/day transdermal oestrogel gel after suppression with gonadotropin releasing hormone agonist. In both groups medication were started in the first day of menstruation cycle and continued until endometrial thickness reached 8 mm. Pregnancy rates (chemical, clinical, and ongoing), abortion rate, live birth rate, and frequency of complications were compared between two groups.
Results: Chemical and clinical pregnancy rates were not significantly different between two groups (p=0.384). The abortion rate was significantly lower in group II than group I (p=0.035). Ongoing pregnancy and the live birth rates were significantly higher in group II (p=0.035). The rate of complication was not different in two groups.
Conclusion: Oestrogel seems to enhance ongoing pregnancy and live birth rates in comparison to estradiol valerate tablet.
Batool Hosein Rashidi, Roya Kabodmehri, Mamak Shariat, Ensieh Shahrokh Tehraninejad, Alireza Abdollahi, Maryam Bagheri, Fedieh Hagholahi,
Volume 17, Issue 3 (March 2019 2019)

Background: Because of the unexpected and often dramatic inhibition of luteinizing hormone (LH) secretion related with the usage of gonadotropin-releasing hormone (GnRH)-antagonist, there has been a probable need for exogenous LH supplementation. There is a basic and clinical evidences that show late development of follicle needs an LH but there is a threshold for LH requirements during folliculogenesis.
Objective: The purpose of this study was to evaluate the changes in serum LH and the identification of patients who benefit from the addition of LH. Materials and Methods: Seventy volunteers for antagonist protocol in IVF cycle were enrolled in this prospective cross-sectional study. The study was carried out in Reproductive Health Research Center, University of Medical Sciences between July 2016 and February 2016. Serum LH level was estimated 24 h before and after the first (GnRH) antagonist injection. The primary outcome was the serum level of LH and its change in the three groups and the secondary outcome was Egg and Embryo quality.
Result: LH changes above or below 50% had no effect on the number of follicle, the number of oocyte, Germinal vesicle oocyte, metaphase 1 oocyte, metaphase 2 oocyte, endometrial thickness, and chemical and clinical pregnancy.
Conclusion: We evaluated the changes of serum LH in the patients who were entered in the antagonist protocol. Our study showed no significant difference in LH levels 24 h before and after the injection of the antagonist between the three groups, and LH changes did not affect the outcome of pregnancy. 

Page 1 from 1     

© 2020 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb